IONIS FB LRx

Drug Profile

IONIS FB LRx

Alternative Names: IONIS-FB-LRx

Latest Information Update: 28 Aug 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Ionis Pharmaceuticals
  • Class Antisense oligonucleotides
  • Mechanism of Action Complement-Factor-B-inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Age-related macular degeneration

Most Recent Events

  • 11 Aug 2017 Ionis Pharmaceuticals plans a phase II trial for Age-related macular degeneration in USA
  • 11 Aug 2017 GlaxoSmithKline declines option to license IONIS FB LRx
  • 11 Aug 2017 Pharmacokinetics data from a phase I trial in Age-related macular degeneration released by Ionis Pharmaceuticals
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top